ISIS

Piper Jaffray Turns Cautious On Isis Pharmaceuticals

In a research report published Wednesday, Piper Jaffray analyst Joshua Schimmer downgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) to Neutral, and reduced the price target to …

Jason Cohen Jason Cohen — February 4, 2015, 11:43 AM EDT

Stock Update (NASDAQ:ISIS): Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of …

Corey Williams — January 14, 2015, 7:47 AM EDT

Stock Update (NASDAQ:ISIS): Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics

(BUSINESS WIRE)–Jan. 9, 2015– Isis Pharmaceuticals, Inc.

Corey Williams — January 9, 2015, 9:43 AM EDT

Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc.

Corey Williams — January 5, 2015, 11:38 AM EDT

Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 33rd Annual J.

Corey Williams — January 3, 2015, 7:32 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts